Herophilus Announces Strategic Transaction with Genentech for Next-Generation Drug Discovery Platform

SAN FRANCISCO–(BUSINESS WIRE)– #biotechnology–Herophilus, a leading biotechnology company with the mission to discover neurotherapeutics to cure complex brain diseases, today announced that Genentech, a member of the Roche Group, has acquired its proprietary high-throughput human organoid-based drug discovery platform comprising the Orchard™, Orchestra™, and OrCA™ technologies. Herophilus will continue to…
Click here to view original post